Dual-Center Development and Validation of a LDL-C and TC Based Nomogram for Preoperative Hemorrhagic Risk in Adult Moyamoya Disease

Why It Matters

Identifying lipid‑related hemorrhagic risk enables earlier intervention and personalized surgical planning, potentially reducing morbidity in a high‑risk MMD population.

Key Takeaways

• LDL‑C above 3.5 mmol/L doubles hemorrhage odds in adult MMD
• Combined LDL‑C/TC nomogram achieves AUC 0.78 for risk prediction
• Study of 260 patients across two Chinese centers identifies lipid risk
• Nomogram offers clinicians a quick tool for pre‑operative stratification

Pulse Analysis

Moyamoya disease, a rare but devastating cerebrovascular disorder, disproportionately affects East Asian adults and carries a high risk of spontaneous intracranial hemorrhage before surgical revascularization. While imaging advances have improved diagnosis, clinicians still lack reliable biomarkers to predict which patients will bleed. Recent epidemiological data suggest that up to 22% of adult MMD cases present with pre‑operative hemorrhage, a complication linked to poor neurological outcomes and increased mortality. Consequently, the search for easily measurable, biologically plausible risk factors has intensified, with lipid metabolism emerging as a promising avenue.

Elevated LDL‑C and total cholesterol have long been implicated in arterial wall degeneration, endothelial dysfunction, and inflammatory cascades that weaken vessel integrity. In the context of MMD’s fragile collateral network, high circulating lipids may exacerbate oxidative stress and matrix metalloproteinase activity, lowering the rupture threshold of abnormal vessels. The study’s finding that LDL‑C levels above 3.5 mmol/L more than double the odds of hemorrhage aligns with broader cardiovascular literature, reinforcing the notion that dyslipidemia is not merely a systemic risk factor but a direct contributor to cerebrovascular fragility in moyamoya patients.

The LDL‑C/TC‑based nomogram translates these biochemical insights into a practical bedside instrument. With an AUC of 0.78, the model offers moderate discriminative power while maintaining simplicity—requiring only two routine lipid measurements. Surgeons can now stratify patients into low, moderate, or high hemorrhagic risk categories, informing decisions about the timing of bypass surgery, peri‑operative blood pressure management, and even pre‑emptive lipid‑lowering therapy. Future work should validate the nomogram in diverse populations and explore whether statin or PCSK9‑inhibitor treatment can modify the identified risk, potentially opening a preventive pharmacologic pathway for a disease traditionally managed surgically.